688166 博瑞医药
已收盘 11-13 15:00:00
资讯
新帖
简况
博瑞医药：控股股东、实际控制人及其一致行动人承诺6个月内不减持股份
同花顺 · 11-12
博瑞医药：控股股东、实际控制人及其一致行动人承诺6个月内不减持股份
博瑞医药：控股股东等承诺6个月内不减持股份
同花顺 · 11-12
博瑞医药：控股股东等承诺6个月内不减持股份
股市必读：博瑞医药新发布《2026年第二次临时股东会会议资料》
证券之星 · 11-12
股市必读：博瑞医药新发布《2026年第二次临时股东会会议资料》
博瑞医药（688166）披露董事会成员调整及董监高责任险购买议案，11月11日股价上涨0.53%
证券之星 · 11-11
博瑞医药（688166）披露董事会成员调整及董监高责任险购买议案，11月11日股价上涨0.53%
单药降糖超越替尔泊肽，联合用药头对头优效于司美格鲁肽，博瑞医药(688166.SH)BGM0504争锋全球降糖标杆
智通财经 · 11-11
单药降糖超越替尔泊肽，联合用药头对头优效于司美格鲁肽，博瑞医药(688166.SH)BGM0504争锋全球降糖标杆
博瑞医药最新公告：BGM0504注射液降糖适应症III期临床试验达预期目标
证券之星 · 11-11
博瑞医药最新公告：BGM0504注射液降糖适应症III期临床试验达预期目标
博瑞医药获得发明专利授权：“一种嘧啶并杂环化合物，包含其的药物组合物及其用途”
证券之星 · 11-07
博瑞医药获得发明专利授权：“一种嘧啶并杂环化合物，包含其的药物组合物及其用途”
股市必读：博瑞医药新发布《关于召开2026年第二次临时股东会的通知》
证券之星 · 11-05
股市必读：博瑞医药新发布《关于召开2026年第二次临时股东会的通知》
博瑞医药（688166）披露召开2026年第二次临时股东大会通知，11月03日股价下跌1.21%
证券之星 · 11-03
博瑞医药（688166）披露召开2026年第二次临时股东大会通知，11月03日股价下跌1.21%
博瑞医药：关于为公司及公司董事、高级管理人员购买责任险的公告
同花顺 · 11-03
博瑞医药：关于为公司及公司董事、高级管理人员购买责任险的公告
博瑞医药(688166.SH)发布前三季度业绩，归母净利润9808万元，同比增长94.92%
智通财经 · 10-29
博瑞医药(688166.SH)发布前三季度业绩，归母净利润9808万元，同比增长94.92%
博瑞医药(688166)9月30日股东户数2.52万户，较上期增加20.3%
证券之星 · 10-29
博瑞医药(688166)9月30日股东户数2.52万户，较上期增加20.3%
博瑞医药（688166）10月27日主力资金净买入27.64万元
证券之星 · 10-28
博瑞医药（688166）10月27日主力资金净买入27.64万元
大健康“A+H”退潮，谁还能上桌？
蓝鲸财经 · 10-15
大健康“A+H”退潮，谁还能上桌？
博瑞医药（688166）10月13日主力资金净卖出753.89万元
证券之星 · 10-14
博瑞医药（688166）10月13日主力资金净卖出753.89万元
股市必读：博瑞医药新发布《自愿披露关于BGM0504片获得药物临床试验批准通知书的公告》
证券之星 · 10-14
股市必读：博瑞医药新发布《自愿披露关于BGM0504片获得药物临床试验批准通知书的公告》
股市必读：博瑞医药新发布《自愿披露关于BGM0504片获得药物临床试验批准通知书的公告》
证券之星 · 10-13
股市必读：博瑞医药新发布《自愿披露关于BGM0504片获得药物临床试验批准通知书的公告》
博瑞医药最新公告：BGM0504片获药物临床试验批准通知书
证券之星 · 10-12
博瑞医药最新公告：BGM0504片获药物临床试验批准通知书
博瑞医药（688166）10月8日主力资金净卖出737.33万元
证券之星 · 10-09
博瑞医药（688166）10月8日主力资金净卖出737.33万元
10月8日博瑞医药跌6.65%，科创创新药ETF国泰基金重仓该股
证券之星 · 10-08
10月8日博瑞医药跌6.65%，科创创新药ETF国泰基金重仓该股
加载更多
公司概况
公司名称：
博瑞生物医药(苏州)股份有限公司
所属行业：
医药制造业
上市日期：
2019-11-08
主营业务：
博瑞生物医药(苏州)股份有限公司的主营业务是医药中间体、原料药和制剂产品的研发、生产。公司的主要产品是创新药BGM0504、BGM1812、恩替卡韦、奥司他韦、卡泊芬净、米卡芬净钠、阿尼芬净、泊沙康唑、依维莫司、吡美莫司、布地奈德、沙美特罗替卡松、噻托溴铵、艾立布林、芦比替定。
发行价格：
12.71
{"stockData":{"symbol":"688166","market":"SH","secType":"STK","nameCN":"博瑞医药","latestPrice":28.9,"timestamp":1794553200000,"preClose":30,"halted":0,"volume":7861419,"delay":0,"changeRate":-0.0367,"floatShares":436000000,"shares":436000000,"eps":0.2347,"marketStatus":"已收盘","change":-1.1,"latestTime":"11-13 15:00:00","open":30.05,"high":30.2,"low":28.86,"amount":231000000,"amplitude":0.0447,"askPrice":28.91,"askSize":3,"bidPrice":28.9,"bidSize":227,"shortable":0,"etf":0,"ttmEps":0.2347,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794792600000},"marketStatusCode":5,"adr":0,"adjPreClose":30,"symbolType":"stock_kcb","openAndCloseTimeList":[[1794533400000,1794540600000],[1794546000000,1794553200000]],"highLimit":33,"lowLimit":27,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":435794991,"isCdr":false,"pbRate":4.07,"roa":"--","peRate":123.135918,"roe":"3.47%","epsLYR":0.13,"committee":0.702576,"marketValue":12594000000,"turnoverRate":0.018,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-11-16。","afterMarket":{"amount":63580,"volume":2200,"close":28.9,"buyVolume":0,"sellVolume":663,"time":1794555237746,"indexStatus":"已收盘 11-13 15:30:00","preClose":30},"floatMarketCap":12594000000},"requestUrl":"/m/hq/s/688166","defaultTab":"news","newsList":[{"id":"2682563175","title":"博瑞医药：控股股东、实际控制人及其一致行动人承诺6个月内不减持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2682563175","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682563175?lang=zh_cn&edition=full","pubTime":"2026-11-12 16:41","pubTimestamp":1794472860,"startTime":"0","endTime":"0","summary":"11月12日，博瑞医药(688166.SH)公告称，公司控股股东、实际控制人袁建栋、实际控制人钟伟芳及其一致行动人博瑞鑫稳自愿承诺，自2026年11月12日至2027年5月11日期间不以任何方式减持其持有的 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261112/c681757068.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261112/c681757068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682174563","title":"博瑞医药：控股股东等承诺6个月内不减持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2682174563","media":"同花顺","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682174563?lang=zh_cn&edition=full","pubTime":"2026-11-12 16:41","pubTimestamp":1794472860,"startTime":"0","endTime":"0","summary":"11月12日，博瑞医药(688166.SH)公告称，公司控股股东、实控人袁建栋、实控人钟伟芳及其一致行动人博瑞鑫稳出具承诺函，自2026年11月12日至2027年5月11日，不以任何方式减持所持公司股份，承 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261112/c681757114.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261112/c681757114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682640581","title":"股市必读：博瑞医药新发布《2026年第二次临时股东会会议资料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2682640581","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682640581?lang=zh_cn&edition=full","pubTime":"2026-11-12 02:26","pubTimestamp":1794421575,"startTime":"0","endTime":"0","summary":"公司公告汇总2026年第二次临时股东会会议资料博瑞生物医药（苏州）股份有限公司召开2026年第二次临时股东会，审议修订《公司章程》及《董事会议事规则》，拟将董事会成员由11名调整为9名，其中独立董事不少于3名；并审议为公司及董事、高级管理人员购买责任险事项，赔偿限额不超过1亿元/年，保险费用不超过50万元/年，授权管理层办理投保相关事宜。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111200002366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682300079","title":"博瑞医药（688166）披露董事会成员调整及董监高责任险购买议案，11月11日股价上涨0.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682300079","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682300079?lang=zh_cn&edition=full","pubTime":"2026-11-11 22:27","pubTimestamp":1794407240,"startTime":"0","endTime":"0","summary":"截至2026年11月11日收盘，博瑞医药报收于30.24元，较前一交易日上涨0.53%，最新总市值为131.78亿元。该股当日开盘30.0元，最高30.47元，最低29.76元，成交额达2.13亿元，换手率为1.62%。近日，博瑞生物医药（苏州）股份有限公司发布2026年第二次临时股东会会议资料。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111100046263.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682132307","title":"单药降糖超越替尔泊肽，联合用药头对头优效于司美格鲁肽，博瑞医药(688166.SH)BGM0504争锋全球降糖标杆","url":"https://stock-news.laohu8.com/highlight/detail?id=2682132307","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682132307?lang=zh_cn&edition=full","pubTime":"2026-11-11 21:48","pubTimestamp":1794404930,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，博瑞医药BGM0504注射液接连取得两项降糖Ⅲ期临床积极结果，将竞争参照指向替尔泊肽和司美格鲁肽两款全球降糖标杆。从单药的较大降幅、高达标率，到联合治疗的直接优效及持续控糖，BGM0504正以两项Ⅲ期研究的数据挑战全球降糖标杆。将这一结果与替尔泊肽单药研究对照，BGM0504的降幅数值表现突出。除平均降幅外，BGM0504的另一项突出表现，是较高的糖化达标比例。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1521947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682308598","title":"博瑞医药最新公告：BGM0504注射液降糖适应症III期临床试验达预期目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2682308598","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682308598?lang=zh_cn&edition=full","pubTime":"2026-11-11 18:11","pubTimestamp":1794391866,"startTime":"0","endTime":"0","summary":"博瑞医药(688166.SH)公告称，公司全资子公司博瑞制药自主研发的BGM0504注射液降糖适应症Ⅲ期临床试验均达成预期目标。两项研究分别针对中国2型糖尿病初治人群及二甲双胍/二甲双胍联合磺脲类药物治疗血糖控制不佳人群，均达到主要终点及所有关键次要终点。目前，BGM0504注射液减重适应症上市申请正处于审评阶段，公司将继续推进降糖适应症的上市申请工作。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111100036871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681816809","title":"博瑞医药获得发明专利授权：“一种嘧啶并杂环化合物，包含其的药物组合物及其用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2681816809","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681816809?lang=zh_cn&edition=full","pubTime":"2026-11-07 11:51","pubTimestamp":1794023501,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示博瑞医药新获得一项发明专利授权，专利名为“一种嘧啶并杂环化合物，包含其的药物组合物及其用途”，专利申请号为CN202110653491.X，授权日为2026年11月6日。本发明所述的化合物，可用于制备成治疗和/或预防癌症的药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110700011884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681066130","title":"股市必读：博瑞医药新发布《关于召开2026年第二次临时股东会的通知》","url":"https://stock-news.laohu8.com/highlight/detail?id=2681066130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681066130?lang=zh_cn&edition=full","pubTime":"2026-11-05 01:04","pubTimestamp":1793811883,"startTime":"0","endTime":"0","summary":"公司公告汇总：公司将于2026年11月20日召开第二次临时股东大会，审议修订《公司章程》及购买董监高责任险两项核心议案；股权登记日为11月13日。公司公告汇总关于召开2026年第二次临时股东会的通知博瑞生物医药（苏州）股份有限公司将于2026年11月20日召开2026年第二次临时股东会，采取现场与网络投票相结合方式，网络投票通过上海证券交易所系统进行。股权登记日为2026年11月13日，登记时间截至11月16日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500002348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680872203","title":"博瑞医药（688166）披露召开2026年第二次临时股东大会通知，11月03日股价下跌1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680872203","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680872203?lang=zh_cn&edition=full","pubTime":"2026-11-03 22:12","pubTimestamp":1793715175,"startTime":"0","endTime":"0","summary":"截至2026年11月3日收盘，博瑞医药报收于29.47元，较前一交易日下跌1.21%，最新总市值为128.43亿元。近日，博瑞生物医药（苏州）股份有限公司发布《关于召开2026年第二次临时股东会的通知》。公告显示，公司将于2026年11月20日召开2026年第二次临时股东会，会议采取现场与网络投票相结合方式，网络投票通过上海证券交易所系统进行。股权登记日为2026年11月13日，登记时间截至2026年11月16日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300045144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680625729","title":"博瑞医药：关于为公司及公司董事、高级管理人员购买责任险的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2680625729","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680625729?lang=zh_cn&edition=full","pubTime":"2026-11-03 20:31","pubTimestamp":1793709060,"startTime":"0","endTime":"0","summary":" 证券日报网讯 11月3日，博瑞医药发布公告称，公司拟延续上年度的做法，继续为公司及全体董事、高级管理人员购买责任保险。赔偿限额：不超过人民币10,000万元/ ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261103/c681421406.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261103/c681421406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679289624","title":"博瑞医药(688166.SH)发布前三季度业绩，归母净利润9808万元，同比增长94.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679289624","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679289624?lang=zh_cn&edition=full","pubTime":"2026-10-29 22:46","pubTimestamp":1793285200,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博瑞医药(688166.SH)披露2026年第三季度报告，前三季度公司实现营业收入9.94亿元，同比增长13.65%;归属于上市公司股东的净利润9808万元，同比增长94.92%;扣非净利润4637万元，同比增长0.44%;基本每股收益0.23元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515604.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679240849","title":"博瑞医药(688166)9月30日股东户数2.52万户，较上期增加20.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679240849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679240849?lang=zh_cn&edition=full","pubTime":"2026-10-29 18:56","pubTimestamp":1793271398,"startTime":"0","endTime":"0","summary":"证券之星消息，近日博瑞医药披露，截至2026年9月30日公司股东户数为2.52万户，较6月30日增加4255.0户，增幅为20.3%。在化学制药行业个股中，博瑞医药股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.95万户。从股价来看，2026年6月30日至2026年9月30日，博瑞医药区间涨幅为2.29%，在此期间股东户数增加4255.0户，增幅为20.3%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900045025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678480425","title":"博瑞医药（688166）10月27日主力资金净买入27.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678480425","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678480425?lang=zh_cn&edition=full","pubTime":"2026-10-28 08:48","pubTimestamp":1793148503,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月27日收盘，博瑞医药报收于29.88元，下跌5.65%，换手率1.93%，成交量8.41万手，成交额2.59亿元。近5日资金流向一览见下表：博瑞医药融资融券信息显示，融资方面，当日融资买入3644.5万元，融资偿还2728.46万元，融资净买入916.04万元。博瑞医药主营业务：原料药、医药中间体和制剂的研发、生产和销售及提供相关技术转让。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800014303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675619300","title":"大健康“A+H”退潮，谁还能上桌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2675619300","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675619300?lang=zh_cn&edition=full","pubTime":"2026-10-15 17:16","pubTimestamp":1792055774,"startTime":"0","endTime":"0","summary":"2026年以来，A股大健康上市公司的赴港上市明显降温。可以说，港股终止上市也没有与该风波有直接关联。该企业负债率约25%，因此市场猜测“A+H”上市的诉求并非缺钱续命，而是全球化战略布局。头部医疗器械、创新药龙头持续坚守“A+H”双平台战略，持续获得机构认可，港股上市成为全球化发展的配套工具。归根结底，大健康板块的“A+H”上市潮退是行情、规则、企业基本面三重因素叠加的结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1792043506360832246","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU2424517915.HKD","LU0650527681.SGD","LU2148510915.USD","LU2348774022.SGD","LU2488822045.USD","BK0229","LU1781817850.SGD","LU1934453819.USD","SGXZ81163826.USD","LU0327786744.USD","LU0405327148.USD","LU0823426480.USD","688639","LU1064131003.USD","LU0823426308.USD","BK0251","688166","LU0605514214.HKD","SGXZ49509284.SGD","LU1997245094.SGD","LU0359202008.SGD","688266","LU1146622755.USD","LU1734074674.USD","IE00B031J352.USD","LU1997245177.USD","LU2213484517.USD","LU0359201612.USD","LU1655091616.SGD","LU1688375341.USD","VXUS","LU1064130708.USD","IE0005HP3H50.USD","BK4585","LU0594300179.USD","LU1979443071.USD","IE00B031HY20.USD","KCAI","BK4588","LU1820825898.SGD","LU0594300419.USD","IE0031814852.USD","IE00B29SXG58.USD","LU2348773727.SGD","IE0008368742.USD","LU0084288322.USD","IPOS","LU0572944931.SGD","300760","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675395780","title":"博瑞医药（688166）10月13日主力资金净卖出753.89万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675395780","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675395780?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:24","pubTimestamp":1791937496,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，博瑞医药报收于31.05元，下跌3.78%，换手率2.01%，成交量8.77万手，成交额2.74亿元。近5日资金流向一览见下表：博瑞医药融资融券信息显示，融资方面，当日融资买入2575.91万元，融资偿还3460.77万元，融资净偿还884.86万元。博瑞医药主营业务：原料药、医药中间体和制剂的研发、生产和销售及提供相关技术转让。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400007152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675692993","title":"股市必读：博瑞医药新发布《自愿披露关于BGM0504片获得药物临床试验批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675692993","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675692993?lang=zh_cn&edition=full","pubTime":"2026-10-14 01:53","pubTimestamp":1791913989,"startTime":"0","endTime":"0","summary":"公司公告汇总：全资子公司收到BGM0504片药物临床试验批准通知书，该药为全球尚无同类靶点口服剂型获批上市的GLP-1/GIP双重激动剂。公司公告汇总自愿披露关于BGM0504片获得药物临床试验批准通知书的公告博瑞生物医药（苏州）股份有限公司全资子公司博瑞制药（苏州）有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意BGM0504片在成人2型糖尿病患者中开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400001656.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675740801","title":"股市必读：博瑞医药新发布《自愿披露关于BGM0504片获得药物临床试验批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675740801","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675740801?lang=zh_cn&edition=full","pubTime":"2026-10-13 01:16","pubTimestamp":1791825375,"startTime":"0","endTime":"0","summary":"公司公告汇总：博瑞医药全资子公司收到BGM0504片药物临床试验批准通知书，该药为全球尚无同类靶点获批上市的GLP-1/GIP双重激动剂口服剂型。公司公告汇总自愿披露关于BGM0504片获得药物临床试验批准通知书的公告博瑞生物医药（苏州）股份有限公司全资子公司博瑞制药（苏州）有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意BGM0504片在成人2型糖尿病患者中开展临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300001640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674877125","title":"博瑞医药最新公告：BGM0504片获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2674877125","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674877125?lang=zh_cn&edition=full","pubTime":"2026-10-12 20:10","pubTimestamp":1791807042,"startTime":"0","endTime":"0","summary":"博瑞医药(688166.SH)公告称，公司全资子公司博瑞制药近日收到国家药监局签发的《药物临床试验批准通知书》，同意BGM0504片在成人2型糖尿病患者中开展临床试验。BGM0504是公司自主研发的GLP-1和GIP受体双重激动剂，其口服剂型全球尚无同类靶点获批上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200031379.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674899918","title":"博瑞医药（688166）10月8日主力资金净卖出737.33万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674899918","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674899918?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:29","pubTimestamp":1791505775,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，博瑞医药报收于33.43元，下跌6.65%，换手率3.01%，成交量13.1万手，成交额4.47亿元。近5日资金流向一览见下表：博瑞医药融资融券信息显示，融资方面，当日融资买入7090.05万元，融资偿还3053.0万元，融资净买入4037.06万元。博瑞医药主营业务：原料药、医药中间体和制剂的研发、生产和销售及提供相关技术转让。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900006161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673220530","title":"10月8日博瑞医药跌6.65%，科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2673220530","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673220530?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:37","pubTimestamp":1791448656,"startTime":"0","endTime":"0","summary":"证券之星消息，10月8日博瑞医药跌6.65%，收盘报33.43元，换手率3.01%，成交量13.1万手，成交额4.47亿元。重仓博瑞医药的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800021274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166","589720"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794744577450,"stockEarnings":[{"period":"1week","weight":-0.0571},{"period":"1month","weight":-0.084},{"period":"3month","weight":-0.2836},{"period":"6month","weight":-0.5365},{"period":"1year","weight":-0.4684},{"period":"ytd","weight":-0.4107}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":-0.0353},{"period":"3month","weight":-0.0746},{"period":"6month","weight":-0.1212},{"period":"1year","weight":-0.0981},{"period":"ytd","weight":-0.0843}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"博瑞生物医药(苏州)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"25218人(较上一季度增加20.30%)","perCapita":"17281股","listingDate":"2019-11-08","address":"江苏省苏州市吴中区工业园区星湖街218号纳米科技园C25栋","registeredCapital":"43579万元","survey":" 博瑞生物医药(苏州)股份有限公司的主营业务是医药中间体、原料药和制剂产品的研发、生产。公司的主要产品是创新药BGM0504、BGM1812、恩替卡韦、奥司他韦、卡泊芬净、米卡芬净钠、阿尼芬净、泊沙康唑、依维莫司、吡美莫司、布地奈德、沙美特罗替卡松、噻托溴铵、艾立布林、芦比替定。","listedPrice":12.71},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博瑞医药(688166)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博瑞医药(688166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博瑞医药,688166,博瑞医药股票,博瑞医药股票老虎,博瑞医药股票老虎国际,博瑞医药行情,博瑞医药股票行情,博瑞医药股价,博瑞医药股市,博瑞医药股票价格,博瑞医药股票交易,博瑞医药股票购买,博瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博瑞医药(688166)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博瑞医药(688166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}